Short answer
Centene Corporation (CNC) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Centene announced second-quarter 2026 results for the period ended June 30, 2026.
Centene Corporation 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Centene announced second-quarter 2026 results for the period ended June 30, 2026
- Full financial results are contained in Exhibit 99.1, the key source for earnings figures and guidance
- Release date July 28, 2026, providing investors with quarterly performance information for valuation updates
Item 5.02 · Departure/Election of Directors or Officers
- Kenneth Burdick resigns July 28, 2026, without dispute, ending his Board and Quality and Compliance Committee service
- Paul Diaz joins Board through 2027 annual meeting, adding healthcare-sector operating and governance experience
- Diaz appointed to Audit and Quality and Compliance Committees, strengthening oversight of financial reporting and healthcare standards
- Diaz’s standard non-employee director compensation applies, with no disclosed related-party transactions or election arrangements
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.2 contains the press release announcing the Item 5.02 officer or director changes
- Investor relevance depends on the affected executive or director, role, and transition terms disclosed in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue rose 4% to $44.4B, while HBR improved to 89.6% from 93.0%, signaling materially better underwriting profitability
- GAAP EPS reached $2.19 versus a $0.51 loss, with adjusted EPS of $2.51 versus a $0.16 loss
- 2026 EPS guidance increased to greater than $3.11 GAAP and greater than $4.80 adjusted, supported by operating strength and approximately $0.50 of non-recurring items
- Commercial HBR improved to 79.2%; Medicare HBR was 89.5%; Medicaid HBR was 93.9%, highlighting segment-specific profitability progress
- Total at-risk membership declined to 25.9M from 28.0M, driven primarily by Marketplace and Medicaid losses despite PDP growth
Item EX-99.2 · Exhibit EX-99.2
- Kenneth A. Burdick retired from Centene’s Board effective July 28, 2026, creating a board-level leadership transition
- Paul J. Diaz joined the Board effective July 28, 2026, adding healthcare operating and public-company governance experience
- Diaz’s background includes CEO roles at Myriad Genetics and Kindred Healthcare, relevant to Centene’s growth and transformation strategy
- Burdick’s departure was attributed to personal priorities and other opportunities, with no disclosed disagreement or strategic dispute
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Centene Corporation 8-K filings
Get the next CNC 8-K as it lands
Follow CNC for push alerts, or ask the research agent what this filing means.